Opus Genetics, Inc. (IRD) stock intrinsic value fair value estimate & owner earnings analysis

Opus Genetics (formerly Ocuphire Pharma) is a clinical-stage eye-disease company with two parts. The first is a gene-therapy pipeline for inherited retinal diseases: OPGx-LCA5 (registrational trial enrolled, dosing expected in the fourth quarter of 2026, topline data by end of 2027) and OPGx-BEST1, which reported positive low-dose results in September 2026 (all five patients showed meaningful visual-function gains, no serious side effects) and, per the company, reached agreement with the FDA on a pivotal endpoint. The second is phentolamine eye drops licensed to Viatris: RYZUMVI, approved in 2023 for reversing pupil dilation, and a presbyopia version whose FDA decision date is October 17, 2026. Opus receives tiered royalties on U.S. sales through 2040 and is eligible for up to $120 million of remaining regulatory and sales milestones. Earnings power: there is none yet. Per-share owner earnings were negative in every year since 2019 except 2022, which was lifted by the one-time $35 million Viatris upfront payment: about -$1.51 (2019), -$2.03 (2020), -$1.45 (2021), +$0.88 (2022), -$0.40 (2023, including a $10 million approval milestone), -$1.20 (2024) and -$0.59 (2025). Operating cash outflow was $24.7 million in the first half of 2026, and revenue is shrinking ($14.2 million in 2025, $2.9 million in the first half of 2026) as Viatris' development reimbursements wind down. The filings do not separate RYZUMVI royalties from other revenue and describe them as small, so we cannot size them and give them no value; a generic challenge from Sandoz goes to trial in January 2027. With no earnings stream to value, we value what can be shown: cash, plus cash from warrants that are deep in the money, less the cost of stopping, less what is owed. Debt: in April 2026 the company borrowed $35 million from Oberland Capital under a facility of up to $155 million, secured on substantially all of its assets, maturing April 2033 with half due in April 2032. Interest is three-month SOFR (floor 3.68%) plus a margin; the interest accrued in the first quarter after funding implies roughly 8.4% a year, half paid in cash and half added to principal for two years. Because that is more than the 6% yardstick we use for all companies, we count the loan at about $39.6 million rather than its $35.3 million balance. Our previous estimate counted the loan at face value because its terms were not yet available; they now are. Up to 10% of the notes can convert into shares at $6.72, which is immaterial. A further $62.1 million on the balance sheet is the accounting value of warrants; it settles in shares, not cash, so it is reflected in the share count, not subtracted. Shares: about 95.5 million shares including pre-funded warrants, plus about 21.4 million warrants at $0.95 and $1.15 that would bring in about $20.5 million if exercised, for about 116.9 million shares fully diluted. Stock options could not be reconciled from the filings available and are left out, which slightly overstates per-share values. Base case, $0.51 per share: we credit no gene-therapy success, no presbyopia approval and no royalty growth, because none is secured today; the BEST1 and LCA5 results, however encouraging, are not yet a product or a contract. The warrants are exercised, adding $20.5 million. From $88.8 million of cash at June 30, 2026, plus warrant cash, less an assumed $10 million to stop trials and close operations, the business is worth about $99.3 million. It owes about $39.6 million. The difference, $59.7 million, is $0.51 per share. Cash spent since June 30 is not deducted because it is not yet reported; at the first-half pace it is roughly $12 million a quarter, or about $0.10 per share each quarter. Bear case, -$0.35 per share: spending continues through the 2027 readouts at about $25 million in the rest of 2026 and $50 million in 2027, LCA5 disappoints at end-2027, Sandoz wins in January 2027 and RYZUMVI royalties fade, and, as in the 2022 biotech funding drought, no new capital can be raised on acceptable terms. The share price falls before the warrants are exercised, so no warrant cash arrives. After an $8 million wind-down about $5.8 million remains, against $39.6 million owed to a lender secured on all the assets. The company would owe about $34 million more than it is worth, and shareholders would receive nothing. Bull case, $0.97 per share: the FDA approves Viatris' presbyopia drops on or near the October 17, 2026 decision date, and launch milestones of about $60 million of the remaining $120 million are received in 2028. The filings do not split the remaining milestones between approval and sales, so this split is our assumption; it is worth about $53.4 million today. Business worth about $152.7 million; owed $39.6 million; difference $113.1 million, or $0.97 per share. Gene-therapy approvals are still left out because nothing secures them. Margin of safety price, $0.25: we are confident about the cash, the warrant terms and the loan, and know almost nothing about future earnings, which today are negative. The worst plausible outcome is the bear case: the company keeps spending about $50 million a year on trials, the trials fail, and a lender with a claim on every asset is paid before shareholders. The structure has no cushion against that: there is no profitable product, one partner (Viatris) supplies all revenue, and the debt is secured. If we are wrong about the wind-down cost, each $10 million moves value by about $0.09 per share; if the warrants are not exercised, base falls to about $0.41. The price assumes a one-to-two-year holding period for the presbyopia decision, the BEST1 second cohort and the LCA5 readout, but the business pays no dividend and spends about $0.10 per share of cash every quarter while waiting. At $0.25 the equity is valued at about $29 million against roughly $60 million of cash left after debt, warrant proceeds and closing costs, which covers around seven months of spending, with the Viatris milestones, the royalty and the gene-therapy programs given no value in that price. Above that, the return depends on trial results we cannot evidence.